TABLE 1.
Comparison of the characteristics of the study subset (n=265) of APIC participants and the full APIC cohort (n=485).
| Site city | Study subset of APIC (N=265) | Overall APIC Population (N=485) |
|---|---|---|
| Baltimore | 53 (20.00%) | 81 (16.70%) |
| Boston | 32 (12.08%) | 65 (13.40%) |
| Chicago | 29 (10.94%) | 58 (11.96%) |
| Cincinnati | 29 (10.94%) | 49 (10.10%) |
| Dallas | 24 (9.06%) | 43 (8.87%) |
| Denver | 29 (10.94%) | 51 (10.52%) |
| Detroit | 24 (9.06%) | 44 (9.07%) |
| New York | 33 (12.45%) | 59 (12.16%) |
| Washington DC | 12 (4.53%) | 35 (7.22%) |
| Gender | ||
| Female | 104 (39.25%) | 205 (42.27%) |
| Male | 161 (60.75%) | 280 (57.73%) |
| Age (years) | ||
| Mean (SD) | 11.0 (3.05) | 10.9 (3.04) |
| Median | 11.0 | 11.0 |
| Q1, Q3 | 8.0, 13.0 | 8.0, 13.0 |
| Range | (6.0–17.0) | (6.0–17.0) |
| Participant race | ||
| Missing | 0 | 1 (0.21%) |
| Black (non-Hispanic) | 168 (63.40%) | 311 (64.12%) |
| Hispanic | 78 (29.43%) | 137 (28.25%) |
| Other/Mixed | 15 (5.66%) | 26 (5.36%) |
| White (non-Hispanic) | 4 (1.51%) | 10 (2.06%) |
| BMI Percentile at Screening | ||
| Number | 265 | 485 |
| Mean (SD) | 75.1 (27.64) | 75.1 (27.40) |
| Median | 88.2 | 87.3 |
| Q1, Q3 | 58.0, 97.5 | 58.0, 97.6 |
| Range | (0.0–99.9) | (0.0–99.9) |
| Income <$15,000 | ||
| Missing | 2 (0.75%) | 2 (0.41%) |
| No | 122 (46.04%) | 222 (45.77%) |
| Yes | 141 (53.21%) | 261 (53.81%) |
| Family history of asthma | ||
| Missing | 6 (2.26%) | 13 (2.68%) |
| No | 67 (25.28%) | 126 (25.98%) |
| Yes | 192 (72.45%) | 346 (71.34%) |
| Eczema diagnosis | ||
| No | 123 (46.42%) | 218 (44.95%) |
| Yes | 142 (53.58%) | 267 (55.05%) |
| Allergic rhinitis diagnosis | ||
| Allergic | 179 (67.55%) | 333 (68.66%) |
| Non-allergic | 86 (32.45%) | 152 (31.34%) |
| Age (months) asthma first diagnosed by doctor | ||
| Number | 264 | 483 |
| Mean (SD) | 42.9 (37.48) | 40.7 (37.34) |
| Median | 36.0 | 24.0 |
| Q1, Q3 | 12.0, 60.0 | 12.0, 60.0 |
| Range | (1.0–180.0) | (1.0–192.0) |
| Controller treatment step | ||
| Number | 265 | 485 |
| Mean (SD) | 3.3 (2.12) | 3.4 (2.06) |
| Median | 3.0 | 4.0 |
| Q1, Q3 | 2.0, 5.0 | 2.0, 5.0 |
| Range | (0.0–6.0) | (0.0–6.0) |
| Number of hospital stays - 12 months | ||
| Number | 265 | 485 |
| Mean (SD) | 0.2 (0.53) | 0.2 (0.55) |
| Median | 0.0 | 0.0 |
| Q1, Q3 | 0.0, 0.0 | 0.0, 0.0 |
| Range | (0.0–5.0) | (0.0–5.0) |
| Any steroid courses (in previous year) | ||
| No | 137 (51.70%) | 257 (52.99%) |
| Yes | 128 (48.30%) | 228 (47.01%) |
| eNO (ppb) at Enrollment | ||
| Number | 243 | 448 |
| Mean (SD) | 29.2 (27.34) | 29.2 (27.90) |
| Median | 19.0 | 19.0 |
| Q1, Q3 | 11.0, 35.5 | 11.0, 35.5 |
| Range | (2.5–137.0) | (2.5–179.0) |
| Baseline - Results of Best Effort - FEV1 (% predicted) at Enrollment | ||
| Number | 264 | 484 |
| Mean (SD) | 95.1 (16.70) | 93.7 (16.44) |
| Median | 94.5 | 94.0 |
| Q1, Q3 | 84.3, 106.0 | 82.8, 104.6 |
| Range | (44.0–136.5) | (39.7–136.5) |
| Baseline - Results of Best Effort - FEV1/FVC at Enrollment | ||
| Number | 259 | 476 |
| Mean (SD) | 80.1 (9.43) | 79.3 (9.25) |
| Median | 80.9 | 80.7 |
| Q1, Q3 | 75.0, 87.0 | 74.3, 85.6 |
| Range | (47.3–97.8) | (45.0–99.9) |
| Total IgE (kUA/L) | ||
| Number | 263 | 478 |
| Mean (SD) | 551.7 (754.12) | 625.0 (860.31) |
| Median | 213.0 | 248.0 |
| Q1, Q3 | 80.0, 719.0 | 91.0, 766.0 |
| Range | (1.0–3852.0) | (1.0–5001.0) |
| Number of allergen sensitivities (panel of 22) -skin test OR IgE - at least 1 non-missing | ||
| Number | 265 | 485 |
| Mean (SD) | 8.2 (6.02) | 8.7 (6.23) |
| Median | 8.0 | 8.0 |
| Q1, Q3 | 2.0, 13.0 | 3.0, 14.0 |
| Range | (0.0–21.0) | (0.0–21.0) |
| sIgE >= 0.35 to any aero allergen | ||
| Missing | 2 (0.75%) | 4 (0.82%) |
| No | 60 (22.64%) | 111 (22.89%) |
| Yes | 203 (76.60%) | 370 (76.29%) |
| sIgE >= 0.35 to any food allergen | ||
| Missing | 3 (1.13%) | 6 (1.24%) |
| No | 138 (52.08%) | 238 (49.07%) |
| Yes | 124 (46.79%) | 241 (49.69%) |
| Final protocol classi fication | ||
| Difficult-to-control | 139 (52.45%) | 253 (52.16%) |
| Easy-to-control | 126 (47.55%) | 232 (47.84%) |